Description
Masitinibisananticancerchemotherapeuticandanti-inflammatorycompoundusedinveterinarymedicine.Masitinibinhibitsc-KitandPDGFR,increasingsurvivaltimeinthetreatmentofmastcelltumorsandothercancers.Invitro,masitinibincreaseslevelsofcaspases3and7,inducingapoptosis.Masitinibalsodecreasesairwayinflammationandedemainfelineallergicasthmamodelsandalsodecreasesthepatient-ratedseverityofmultiplesclerosisinclinicalsettings.MasitinibalsoexhibitspotentialefficacyagainstAlzheimer’sdiseasewhengivenasanadjuncttherapy,slowingcognitivedecline.
References
SmrkovskiOA,EssickL,RohrbachBW,etal.Masitinibmesylateformetastaticandnon-resectablecaninecutaneousmastcelltumours.VetCompOncol.2013Jul12.[Epubaheadofprint].PMID:23845124.
FaheyCE,MilnerRJ,KowK,etal.Apoptoticeffectsofthetyrosinekinaseinhibitor,masitinibmesylate,oncanineosteosarcomacells.AnticancerDrugs.2013Jun;24(5):519-26.PMID:23466652.
VermerschP,BenrabahR,SchmidtN,etal.Masitinibtreatmentinpatientswithprogressivemultiplesclerosis:arandomizedpilotstudy.BMCNeurol.2012Jun12;12:36.PMID:22691628.
Lee-FowlerTM,GunturV,DodamJ,etal.Thetyrosinekinaseinhibitormasitinibbluntsairwayinflammationandimprovesassociatedlungmechanicsinafelinemodelofchronicallergicasthma.IntArchAllergyImmunol.2012;158(4):369-74.PMID:22487554.
CadotP,HenselP,BensignorE,etal.Masitinibdecreasessignsofcanineatopicdermatitis:amulticentre,randomized,double-blind,placebo-controlledphase3trial.VetDermatol.2011Dec;22(6):554-64.PMID:21668810.
PietteF,BelminJ,VincentH,etal.Masitinibasanadjuncttherapyformild-to-moderateAlzheimer"sdisease:arandomised,placebo-controlledphase2trial.AlzheimersResTher.2011Apr19;3(2):16.PMID:21504563.
